NASDAQ:UMRX - Unum Therapeutics Stock Price, News & Analysis

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Unum Therapeutics Inc (NASDAQ:UMRX) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.05. The company earned $3.14 million during the quarter, compared to analyst estimates of $3.10 million. Unum Therapeutics had a negative net margin of 340.49% and a negative return on equity of 75.60%. View Unum Therapeutics' Earnings History.

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Unum Therapeutics.

5 brokers have issued twelve-month price targets for Unum Therapeutics' shares. Their predictions range from $6.00 to $21.00. On average, they anticipate Unum Therapeutics' share price to reach $14.50 in the next year. This suggests a possible upside of 748.0% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.

Media stories about UMRX stock have been trending positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Unum Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Unum Therapeutics.

Unum Therapeutics saw a drop in short interest in the month of July. As of July 15th, there was short interest totalling 518,700 shares, a drop of 66.0% from the June 15th total of 1,523,600 shares. Based on an average daily trading volume, of 194,500 shares, the short-interest ratio is currently 2.7 days. Approximately 4.6% of the shares of the stock are sold short. View Unum Therapeutics' Current Options Chain.

Some companies that are related to Unum Therapeutics include NuCana (NCNA), Concert Pharmaceuticals (CNCE), PhaseBio Pharmaceuticals (PHAS), Aratana Therapeutics (PETX), Fulcrum Therapeutics (FULC), Forty Seven (FTSV), Urovant Sciences (UROV), Aeglea Bio Therapeutics (AGLE), Evofem Biosciences (EVFM), Chiasma (CHMA), Xenon Pharmaceuticals (XENE), Verrica Pharmaceuticals (VRCA), Evelo Biosciences (EVLO), Ocular Therapeutix (OCUL) and Kamada (KMDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include Vistagen Therapeutics (VTGN), Highpower International (HPJ), KemPharm (KMPH), Adaptimmune Therapeutics (ADAP), Allena Pharmaceuticals (ALNA), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), SCYNEXIS (SCYX) and Tandem Diabetes Care (TNDM).

(UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Unum Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.17%), Vanguard Group Inc. (1.35%), Northern Trust Corp (0.58%), Platinum Investment Management Ltd. (0.56%), Paloma Partners Management Co (0.29%) and Jane Street Group LLC (0.17%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.

UMRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Platinum Investment Management Ltd., Jacobs Levy Equity Management Inc., Vanguard Group Inc., Wells Fargo & Company MN, Morgan Stanley and Northern Trust Corp. View Insider Buying and Selling for Unum Therapeutics.

UMRX stock was acquired by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, Jane Street Group LLC, Susquehanna International Group LLP and Acadian Asset Management LLC. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of UMRX stock can currently be purchased for approximately $1.71.

Unum Therapeutics has a market capitalization of $52.43 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.

The official website for Unum Therapeutics is http://www.unumrx.com/.

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]